cost plus drugs glp 1 partners with 9amHealth on obesity care drugs True Rx Health Strategists |

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

Introduction Diabetes is a chronic disease that occurs when the pancreas does not produce ade

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had come to rely on compounded versions is increasingly uncertain.

Learn what research says about breast milk transfer, milk supply, nutrition, and postpartum weight loss.

Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity